By Wholesale Investor
In the high-octane world of biotechnology, success is often measured by the narrowest of margins. But for Dr. Ian Nisbet, CEO of Melbourne-based Cartherics Pty Ltd, the mission is defined by a gap so large it has become a “tragic” outlier in modern medicine: the chronic underfunding of women’s health.
Ovarian cancer, often called […]
Cartherics is pleased to share Dr Ian Nisbet’s presentation at the Emergence Investment Conference in Sydney, where he outlined the Company’s strategy, progress and vision for transforming women’s health through pioneering cellular immunotherapies.
Speaking to an audience of investors and industry leaders, Dr Nisbet highlighted Cartherics’ unique focus on developing off-the-shelf cell therapies designed specifically to […]
Cartherics is pleased to announce that Professor Alan Trounson AO, Deputy Chair, will deliver an invited lecture at King Abdullah University of Science and Technology (KAUST) titled: A Platform Technology for Immune Targeting Cancer and Endometriosis – A Women’s Health Focus. The lecture will take place on February 4, at 10.30am (AST).
In this lecture, Professor […]
Cartherics is pleased to announce that Dr Madeline Cao, Head of Manufacturing Development and Dr Walid Azar, Chief Scientific Officer, will present at the upcoming ANZ Biologics Festival in Melbourne, showcasing Cartherics’ progress in building a discovery-to-clinic engine for scalable, off-the-shelf cell therapies.
Dr. Cao will deliver a presentation titled, ‘Off-the-Shelf’ Immuno-Cell Therapies: Manufacturing […]
Melbourne, Australia, 16 December 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead […]
Melbourne, Australia, 8 December 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and […]
Cartherics is pleased to announce that it will be presenting at the 8th Australian and New Zealand Society for Extracellular Vesicles (ANZSEV) 2025 Conference in Wellington, New Zealand. ANZSEV 2025 will showcase advances in the field across EVs and biological nanoparticles – their role in cell biology, advances in technologies for their purification and […]
In the lead-up to BIO, Cartherics’ COO, Dr Ian Nisbet was interviewed by BioSpectrum Asia to discuss the company’s innovative approach to cell therapy development. He discusses the transformative potential of CAR-NK cell therapies in treating solid tumours and endometriosis. These engineered natural killer cells, derived from iPSCs, are designed to target and eliminate cancer […]
Melbourne, Australia, 28 May 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company focused on developing immune cell therapies for cancer and other diseases, announced today that Dr. Ian Nisbet, […]
Cartherics’ Chief Operating Officer, Dr. Ian Nisbet recently presented at the 3rd ANZ Biologics Festival at Crown Promenade in Melbourne. His presentation titled, ‘Building a Discovery-to-Clinic Company to Exploit the Full Power of Cell Therapies’ provided insights into Cartherics’ innovative approach to clinical manufacturing and cell therapy development.
The 3rd ANZ Biologics Festival brought together biopharma […]
Cartherics’ mission is the development of novel, immune cell therapy products for the treatment of cancer and endometriosis.
Stay informed about our latest news and developments
© Copyright 2022 – 2026| Cartherics Pty Ltd
